Description du projet
Une plateforme in-silico innovante pour la conception d’échafaudages vasculaires biorésorbables à élution médicamenteuse
L’athérosclérose constitue un grave problème pour les individus en Europe et dans le monde. Il est donc urgent de trouver des solutions innovantes pour améliorer le traitement et la qualité de vie des patients. Le projet InSilc, financé par l’UE, travaille actuellement à l’élaboration d’une plateforme d’essais cliniques in-silico pour aider les chercheurs, les cardiologues et les experts de l’industrie biomédicale à concevoir, développer et évaluer des échafaudages vasculaires biorésorbables à élution médicamenteuse. Pour atteindre cet objectif, une modélisation informatique avancée et des connaissances biomédicales et biologiques complètes seront utilisées pour simuler les performances de l’implantation d’un stent dans des anatomies cardiovasculaires spécifiques au patient. L’introduction de la plateforme InSilc apportera des améliorations significatives dans l’approche thérapeutique de l’implantation de stents, qui se traduira par une réduction des coûts directs et indirects des soins de santé.
Objectif
The aim of InSilc is to develop an in-silico clinical trial (ISCT) platform for designing, developing and assessing drug-eluting bioresorbable vascular scaffolds (BVS), by building on the comprehensive biological and biomedical knowledge and advanced modelling approaches to simulate their implantation performance in the individual cardiovascular physiology. The InSilc platform is based on the extension of existing multidisciplinary and multiscale models for simulating the drug-eluting BVS mechanical behaviour, the deployment and degradation, the fluid dynamics in the micro- and macroscale, and the myocardial perfusion, for predicting its interaction with the vascular wall in the short- and medium/long term. InSilc goes beyond the design and development of ISCT and lays on the generation of in-silico models for obtaining quick and informed answers to several “What if” scenarios. “Virtual” patients would be given a “virtual” drug-eluting BVS, for observing the performance of the scaffold, assess and quantify the intended effect, with a deeper understanding than normal trials can provide. By integrating the information obtained from different in-silico predictive models, InSilc will: (i) assist in the development, assessment and optimization of the drug-eluting BVS and deliver accurate and reliable information to the Stent Biomedical Industry, (ii) assist the interventional Cardiologists in improving the surgical process of drug-eluting BVS implantation, support them in the clinical assessment and reduce the complications of suboptimal scaffold performance. By introducing computer simulations for establishing the safety and efficacy of drug-eluting BVS, InSilc aims to lower development costs and shorten time-to-market, reduce, refine, and partially replace human clinical trials through a more effective human clinical trials design, reduce the need for animal testing and result in a significant reduction of the associated direct and indirect costs.
Champ scientifique
- medical and health sciencesclinical medicineangiologyvascular diseases
- natural sciencesphysical sciencesclassical mechanicsfluid mechanicsfluid dynamics
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesbasic medicinephysiology
- natural sciencesmathematicsapplied mathematicsstatistics and probability
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
70013 Irakleio
Grèce